Tildrakizumab in PsA
Presenter: Philip Mease, University of Washington, Seattle, USA.
Wednesday 12 June: 16:15–17:45 (Abstract LB0002)
In this study, patients with active psoriatic arthritis were randomly assigned to receive tildrakizumab (SUNPG1623) at doses ranging from 200 mg every 4 weeks to 20 mg every 12 weeks, or to receive placebo. The two primary outcomes are the proportion of patients with an ACR20 response at week 24 and the occurrence of adverse events.
- News story | Tildrakizumab shows promise for PsA
- Clinical trial commentary | LISTEN: Tildrakizumab trial lead investigator Philip Mease outlines the results
- External link | Conference abstract
- External link | ClinicalTrials.gov registration page